Amanta Healthcare Q2 FY27 Revenue Rs 83 Cr, PAT Rs 4.86 Cr
Amanta Healthcare reported Q2 FY27 revenue of ₹83.13 Cr (up 17.3% YoY) and PAT of ₹4.86 Cr. H1 FY27 revenue reached ₹151.94 Cr with PAT of ₹8.17 Cr. SteriPort Line 3 is now live, increasing capacity by 75%, with SVP expansion planned for Q1 FY28. The company aims for 20%+ revenue CAGR and 25%+ EBITDA margin.
The financial results show positive growth, and capacity expansions are significant. However, the impact is considered medium as it is primarily an update on operational performance and strategic initiatives rather than a transformative event like a major acquisition or merger.
The company reported strong year-on-year growth in revenue and PAT for the quarter and half-year. Strategic capacity expansions and operational efficiencies like captive solar power are expected to drive future growth, leading to a positive outlook.
Amanta Healthcare Limited has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a revenue of ₹83.13 crore for Q2 FY27, marking a 17.3% year-on-year increase. EBITDA stood at ₹17.95 crore with a margin of 21.6%, leading to a Profit After Tax (PAT) of ₹4.86 crore and a PAT margin of 6% for the quarter.
For the half-year ended September 30, 2026 (H1 FY27), the company's revenue was ₹151.94 crore, with a PAT of ₹8.17 crore. The presentation also highlighted strategic initiatives, including the commissioning of SteriPort Line 3 in early September 2026, which increases SteriPort capacity by 75% to 11.6 crore bottles. This new line is expected to generate approximately ₹60 crore in revenue in FY27 and ₹110-120 crore annually at optimal utilization.
Further expansion is planned with the SVP project, set to increase capacity from 20.9 crore to 31.7 crore units during Q1 of FY28. This expansion will add inhalation and ophthalmics to the highest-margin segment. The company also noted the operationalization of its 10.8 MW captive solar plant since the end of Q1 FY27, projecting annual power savings of around ₹9 crore. The debt-to-equity ratio has improved significantly, decreasing from 3.5x in FY23 to approximately 1.1x in FY26. Amanta Healthcare has set a two-year target of achieving a revenue CAGR of over 20% and an EBITDA margin exceeding 25%.
What to do with a filing like this
Amanta Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Amanta Healthcare Limited. Read the original for the full detail.